(NASDAQ: RARE) Ultragenyx Pharmaceutical's forecast annual revenue growth rate of 22.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.51%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Ultragenyx Pharmaceutical's revenue in 2025 is $610,159,000.On average, 9 Wall Street analysts forecast RARE's revenue for 2025 to be $63,432,586,396, with the lowest RARE revenue forecast at $62,631,930,786, and the highest RARE revenue forecast at $64,367,584,076. On average, 9 Wall Street analysts forecast RARE's revenue for 2026 to be $75,984,800,153, with the lowest RARE revenue forecast at $68,305,329,409, and the highest RARE revenue forecast at $81,527,518,829.
In 2027, RARE is forecast to generate $113,143,971,004 in revenue, with the lowest revenue forecast at $75,013,759,478 and the highest revenue forecast at $138,088,999,822.